DT-216P2

· Design Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for DT-216P2, covering 2025-02-21 to 2025-05-18. Get the full timeline:

Most recent: Clinical Trial Update: A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia [Phase 1, Phase 2]